About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Eurasian Hematology-Oncology Group
http://www.ehog.net/
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Leukemia
Lymphoma
Myeloma
MDS and MPN
Benign Hematology
Videos
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Leukemia
Lymphoma
Myeloma
MDS and MPN
Benign Hematology
Videos
8th Eurasian Hematology Oncology Summit
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Palliative & Supportive Care
COVID-19
Basic Science
Leukemia
Lymphoma
Myeloma
MDS and MPN
Benign Hematology
Lung
Business
7th Eurasian Hematology Oncology Summit
COVID-19
Leukemia
Lymphoma
Myeloma
MDS and MPN
Xth Eurasian Hematology-Oncology Congress
Breast
Lung
Hematologic Oncology
Gastrointestinal
Genitourinary
General Oncology
Sarcoma
Skin
Head & Neck
Events
Myeloma
15:54
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
MRD in Newly Diagnosed MM: MRI vs. PET/CT, RVD+/-ASCT, Dara+Len to Revert MRD+ to MRD-, Correlation Between Levels and Outcomes
FEATURING
Evangelos Terpos
12 views
January 15, 2021
14:53
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
miRNAs in MM: Dysregulated miRNA Expression Cancer Cells, miR-221/222 Cluster in More Favorable Prognosis, miR-15a & miR-16 in Bone Disease
FEATURING
Aristea-Maria Papanota
16 views
January 12, 2021
23:52
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Decision Making in R/R MM: What Options to Consider for 1st Relapse in Disease not Refractory to Lenalidomide, First Relapse in Lenalidomide-Refractory Disease, or After 2+ Prior Therapies?
FEATURING
Angelo Maiolino
43 views
January 11, 2021
16:34
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Frontline MM Updates: What Are the Benefits of Long-Term, Continuous Therapy? Will D-VTd Increase CRR After Consolidation? How to Manage Newly Diagnosed Transplant Candidates?
FEATURING
Maria-Victoria Mateos
139 views
January 11, 2021
1